Members log in

Remember me

Do not refresh my screen on timeout

close

News

Nomination for ABN Honorary Secretary and Honorary Treasurer are now open. Please do consider if you could stand, or could encourage a colleague to stand for these important roles.

Read More

Events

Save the date Wednesday 9 - Friday 11 May 2018.

Read More

ABN MS Guidelines 2015

The ABN Revised (2015) Guidelines for Prescribing Disease-Modifying Treatments in Multiple Sclerosis are scheduled for publication in the August Edition of Practical Neurology and are now available on the journal and on the ABN website .

New guidelines move forward treatment of multiple sclerosis

 The Association of British Neurologists (ABN) revised prescribing guidelines for the treatment of relapsing-remitting MS (RRMS) have been published by the journal Practical Neurology

 

NEW guidelines for neurologists on drug treatment for RRMS clarify the complex treatment landscape and stress the importance of patient involvement in decision making.

In the last 20 years the UK has gone from having no available treatments for RRMS to having eleven. More recently, the treatment of RRMS has altered radically:  several new drugs—effective—but also with some significant risks and side-effects - have gained licences. The ABN has responded with a major revision of the guidelines on how these drugs should be used and monitored in MS services across the UK. The guidelines stress the increasing importance of prompt treatment following diagnosis and that people with MS will face complex choices and must play an active role in treatment decisions.

The ABN has also sought the input and advice from the two major UK MS patient groups, the MS Society and the MS Trust and has acknowledged their contribution to and their support for the revisions. This approach reflects the strong commitment amongst MS neurologists to the involvement of people living with MS in what can be complex and difficult choices.

MS is the most common disabling neurological condition affecting young adults in the western world, with over 100,000 people with the condition in the UK. Around 85% of people are initially diagnosed with RRMS which causes distinct attacks of symptoms which then fade away either partially or completely.

The DMTs vary in efficacy, side effects, administration and monitoring and have been categorised accordingly to treat relapse-remitting MS and more active relapsing-remitting MS.

The guidelines recommend starting treatment as early as possible in eligible patients. Everyone diagnosed with MS should have timely access to MS teams, including neurologists and MS specialist nurses. The guidelines also recommend more consistent use of MRI scanning to monitor and assess the effectiveness of treatment.

The UK is ranked 25 out of 27 European countries on the proportion of people with RRMS using DMTs.

Prof. Phil Smith, President, ABN

 

“Over the past two decades, clinicians working in partnership with the pharmaceutical industry have continued to develop, to test, and to make available new drugs for treating multiple sclerosis, extending substantially the range of effective agents available for relapsing–remitting disease. The ABN warmly applauds these successful endeavours and welcomes this significant improvement in the treatment landscape for MS.”

 

“Some of these new drugs are complex, a few carrying the small but real risk of serious side effects: this, in combination with the now large number of therapeutic options, has made the choice of the right drug for each individual patient more challenging and complicated than ever before, both for patient and neurologist. We sincerely hope that the 2015 ABN MS treatment guidelines will inform and guide these difficult choices.”

 

Nick Rijke, Executive Director of Policy and Research, MS Society

 

“We are very pleased the ABN recommends early treatment of MS with DMTs and recognises the importance of shared decision-making between neurologist and patient when deciding which route to take. We also welcome the emphasis on MRI scanning to support diagnosis and make better treatment decisions. The combination of these recommendations should help ensure fast diagnosis and appropriate, timely treatment for people with MS.”

 

Amy Bowen, Director of Service Development, MS Trust

 

“The revised guidelines from the ABN herald a new era in MS care. Treatment choices are increasingly complex and expert guidance is vital to ensure people with MS can make the choices that are right for them. People with MS will need swifter access to neurologists and MS specialist nurses who can support them to understand their options, including the implications of leaving their disease untreated. “

 

For Press Enquiries, please contact:

 

MS   Society

MS   Trust

ABN

Clare   Keeling

Press   and PR Officer

 

T +44(0)20 8827 0208

E clare.keeling@mssociety.org.uk

Rosie   Ireland

Weber-Shandwick

 

T +44 (0)20   7067 0190
  M +44 (0)7590 228701

E rireland@webershandwick.com  

ABN Office

 

 

T +44(0)20 7405 4060

E info@thabn.org

 

 

 

 

 

 

News

Nomination for ABN Honorary Secretary and Honorary Treasurer are now open. Please do consider if you could stand, or could encourage a colleague to stand for these important roles.

Read More

Events

Save the date Wednesday 9 - Friday 11 May 2018.

Read More